HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) An erratum has been published Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by VISSER, T. J. Articles by HENNEMANN, G. Search for Related Content PubMed Articles by VISSER, T. J. Articles by HENNEMANN, G.

Department of Internal Medicine III and Clinical Endocrinology, Medical Faculty, Erasmus University, Rotterdam, The Netherlands

(Received 19 November 1976)

Recently data have suggested that in man the contribution to the overall turnover of thyroxine (T₄) of pathways along which this prohormone is converted either into metabolically active 3,3',5-tri-iodothyronine (T₃) or into inactive 3,3',5'-tri-iodothyronine (reverse T₃, rT₃) is under physiological control. We describe here the synthesis of [¹²⁵I]rT₃ and the production and characterization of antisera raised against an rT ₃-bovine serum albumin (rT₃-BSA) conjugate.

3,3',5'-Tri-iodo-L-thyronine-BSA, prepared essentially according to the method of Olivier, Parker, Brasfield & Parker (1968), L-rT₃ and 3,3'-di-iodo-L-thyronine (3,3'-T₂) were obtained by courtesy of Dr E. Scheiffele (Henning GmbH., Berlin); L-T₄ and L-T₃ were purchased from Sigma Chemical Co. (St Louis, Missouri, U.S.A.); 3-iodo-L-tyrosine (MIT) and 3,5-di-iodo-L-tyrosine (DIT) were obtained from Calbiochem AG (Lucerne, Switzerland); Na¹²⁵I (sp.act. approximately 14 mCi/µg) from The Radiochemical Centre (Amersham) and goat anti-rabbit